Neurocrine Q3 2022: INGREZZA sales $376M, GAAP EPS $0.69; raises FY guidance

NEUROCRINE BIOSCIENCES INC

2022-Q3 EPS reported $0.67 revenue$1,076,700,000

Q3 INGREZZA net product sales $376M (+31% YoY); TRx ~68,600 (+32% YoY).
GAAP net income $68.5M ($0.69 diluted EPS); non-GAAP net income $106.7M ($1.08 EPS).
Total revenue $387.9M, up 31% from $296.0M in Q3 2021.
Raised 2022 INGREZZA sales guidance to $1.400-$1.425B; R&D & SG&A guidance reaffirmed.
Acquired Diurnal Group plc for ~£48.3M (~$56M); sNDA for valbenazine in Huntington chorea submitted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEUROCRINE BIOSCIENCES INC reported Third quarter ended September 30, 2022 results: revenue Total revenues $ 387.9, net income GAAP net income $ 68.5, EPS GAAP earnings per share – diluted $ 0.69.

Period: Third quarter ended September 30, 2022
Revenue: Total revenues $ 387.9
Net income: GAAP net income $ 68.5
EPS: GAAP earnings per share – diluted $ 0.69
Result: reported results

Exact text from the filing

Total revenues $ 387.9 $ 296.0 $ 1,076.7 $ 821.5 GAAP Research and Development (R&D) $ 107.7 $ 92.7 $ 345.8 $ 240.7 Non-GAAP R&D $ 92.8 $ 80.7 $ 302.2 $ 204.5 GAAP Selling, General and Administrative (SG&A) $ 186.3 $ 154.6 $ 569.8 $ 426.8 Non-GAAP SG&A $ 158.1 $ 129.5 $ 483.8 $ 364.4 GAAP net income $ 68.5 $ 22.5 $ 65.5 $ 96.9 GAAP earnings per share – diluted $ 0.69 $ 0.23 $ 0.67 $ 0.99

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEUROCRINE BIOSCIENCES INC reported Fiscal year 2022 results: revenue INGREZZA Net Product Sales 1 $ 1,400 $ 1,425. Guidance raised.

Period: Fiscal year 2022
Revenue: INGREZZA Net Product Sales 1 $ 1,400 $ 1,425
Guidance: raised
Result: guidance update

Exact text from the filing

Updated 2022 INGREZZA Sales and Reaffirmed Operating Expense Guidance: Range (in millions) Low High INGREZZA Net Product Sales 1 $ 1,400 $ 1,425 GAAP R&D expense 2 $ 415 $ 450 Non-GAAP R&D expense 3 $ 360 $ 395 GAAP SG&A expense $ 720 $ 735 Non-GAAP SG&A expense 3 $ 605 $ 620 1.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-22-000055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.